Toripalimab after esophageal cancer surgery
Part of Cancer, Digestive system clinical trials.
This trial tests a drug called Toripalimab given after surgery for esophageal cancer to see if it helps prevent the cancer from coming back. It's for people who already had chemotherapy and immunotherapy before surgery and had all the cancer removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You had esophageal cancer (squamous cell type) that was removable, and you had 2 cycles of immunotherapy plus chemo before surgery, and all cancer was removed (R0).
- Your blood tests show good bone marrow, liver, and kidney function.
- You have not had any other cancer treatment (chemo, radiation, hormone therapy) after surgery, and have no other active cancer.
- You are in good physical condition (ECOG score 0 or 1).
- You agree to use birth control during the study and for 6 months after (if you can have children).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the immunotherapy drug toripalimab and the chemotherapy pill capecitabine after standard chemoradiotherapy can help prevent esophageal cancer from coming back. It's for people with squamous cell esophageal cancer that hasn't spread far and who have just finished chemoradiotherapy.
This trial tests whether the immunotherapy drug Toripalimab can help prevent esophageal cancer from returning after successful surgery and chemotherapy. It is for people whose cancer completely disappeared (pathological complete response) after pre-surgery treatment.
This trial tests whether adding the immunotherapy drug toripalimab to standard chemoradiation before surgery helps people with a type of esophageal cancer. It is for patients whose cancer has not spread to other organs and who have not had treatment before.
This trial tests adding an immunotherapy drug (toripalimab) to chemotherapy and low-dose radiation for people with esophageal cancer that did not shrink after initial treatment. The goal is to see if this combination can help when standard therapy stops working.
This trial is for people with advanced esophageal cancer that hasn't spread far. After initial treatment with chemotherapy, immunotherapy, and radiation, you'll either get toripalimab or just be watched to see which approach works better.
This study tests whether adding a drug called toripalimab after standard chemoradiation can help older adults with esophageal cancer. The goal is to see if this treatment can keep the cancer from coming back after initial therapy.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.